Cellectar Biosciences (CLRB) Earnings Date & Reports

Key Takeaways

• Cellectar Biosciences reported a third-quarter 2026 net loss of $8.0 million, or $0.46 per share, matching the consensus estimate of a $0.46 loss.
• The net loss widened from $4.4 million, or $1.41 per share, in the same quarter a year earlier, largely on higher clinical-trial spending.
• Research and development (R&D) expense rose to $5.4 million from $2.5 million a year ago, driven by the Phase 3 confirmatory trial and the CLR 125 breast-cancer study.
• Cash and cash equivalents stood at $24.6 million as of September 30, 2026, which management says funds operations into the second quarter of 2027.
• The company reaffirmed plans to dose the first patient in its Phase 3 trial in the first quarter of 2027 and to file for U.S. accelerated approval in the first half of 2027.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to discover AI-driven trading strategies for stocks and ETFs.

Earnings Context and Why It Matters

Cellectar Biosciences is a late-stage clinical biopharmaceutical company with no product revenue, so its quarterly results are read less for sales growth and more for cash burn, trial progress, and regulatory momentum. The company is advancing its lead drug candidate, iopofosine I 131, as a treatment for Waldenström macroglobulinemia (WM), a rare blood cancer. Investors watch each report closely because the share price is tied to clinical milestones and the path toward a New Drug Application (NDA). With spending rising into a confirmatory Phase 3 trial and a cash runway extending only into mid-2027, this report matters as a gauge of whether the company can reach key value-creating catalysts before needing more capital.

Reported Results

For the three months ended September 30, 2026, Cellectar reported a net loss attributable to common stockholders of $8.0 million, or $0.46 per basic and diluted share, compared with a loss of $4.4 million, or $1.41 per share, in the prior-year quarter. The result matched the analyst consensus of a $0.46 loss per share. The company generated no revenue during the period.

R&D expenses increased to $5.4 million from $2.5 million a year earlier, reflecting the initiation of the Phase 3 confirmatory trial of iopofosine I 131 and higher activity in the Phase 1b CLR 125 study in triple-negative breast cancer (TNBC). General and administrative (G&A) expenses rose modestly to $2.7 million from $2.3 million, mainly on higher professional fees and personnel costs.

As of September 30, 2026, cash and cash equivalents totaled $24.6 million, up from $13.2 million at the end of 2025, following a May 2026 financing. Management reiterated that this balance is adequate to fund budgeted operations into the second quarter of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage names like Cellectar, it offers a structured way to surface and compare opportunities across the biotechnology sector. Explore the AI Screener to refine your own market research.

Market Reaction and Investor Sentiment

The in-line earnings print leaves investor attention focused on execution and timeline risk rather than the headline loss. Cellectar's stock has traded under significant pressure in recent months, reflecting concerns about its cash runway and the funding conditions tied to milestone-based warrants. While Phase 2b data for iopofosine I 131 remain supportive, the market has shown sensitivity to any slippage in clinical and regulatory timelines. Key risk factors include the need to raise additional capital, the share-price thresholds required to unlock warrant proceeds, and the regulatory path toward accelerated approval. Sentiment is likely to remain cautious until the company demonstrates concrete progress on first-patient dosing in its Phase 3 trial.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important catalyst is the planned dosing of the first patient in the confirmatory Phase 3 trial of iopofosine I 131, now targeted for the first quarter of 2027. This trial will enroll 100 patients per arm and use progression-free survival as its primary endpoint.

Management also plans to submit an NDA in the first half of 2027 seeking accelerated approval for the post-second-line, post-BTK-inhibitor Waldenström macroglobulinemia population. The company recently reported a 87.5% overall response rate and a 16.0-month median duration of response in patients evaluated immediately after BTK-inhibitor therapy.

Investors should monitor spending closely, as R&D costs are rising with the Phase 3 startup and the CLR 125 TNBC trial. With a cash runway extending only into the second quarter of 2027, the company may need additional financing before reaching its key regulatory milestones. Any delays in trial enrollment or regulatory filing timelines, as well as updates on the CLR 125 program, could shape the stock's direction over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations